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A long-standing goal of the HIV field has been to develop a vaccine; however, there has been limited success in 
this pursuit, to date. The HIV-1 envelope glycoprotein (Env) is the only HIV viral protein known to elicit broadly 
neutralizing antibodies (bNAbs) and as such Env is the only candidate molecule for vaccine design. Recent 
advances have been made for stable expression of this recombinant protein in its closed, pre-fusion native viral 
surface conformation, with the current work focusing on the BG505-DS-SOSIP.664 construct developed at the 
NIH. The HIV-1 Env is a trimeric construct containing approximately 90 N-linked glycans accounting for over 
50% of the protein mass. This glycan profile is an essential determinant for viral infection, with Env having a 
predominantly oligomannose glycan composition.  Specific glycans are utilized for the binding epitopes of 
several bNAbs, indicating the importance of the glycosylation profile in a potential vaccine candidate.  Utilizing 
DoE principles, a media supplement screen was carried out in shake flasks and ambr®15 micro bioreactors to 
investigate magnesium and manganese cations, monosaccharides, and higher nutrient supplementation on the 
Env glycosylation profile. These screens identified that supplementation with mannose could significantly 
improve the quantity and quality of the recombinant protein, but other nutrient feeds and hexose sugars, such as 
glucose or fructose, did not provide a similar benefit. Glycan profile analysis confirmed that the benefit of 
mannose can be attributed to the shift in the glycan profile to increased oligomannose species. Additional 
studies are planned to optimize the mannose and other monosaccharide supplementations with the ultimate 
goal to incorporate the results into a GMP manufacturing process.  
 
   
  
 
Figure 1. Broadly neutralizing 
antibodies that have glycan 
dependent binding epitopes 
have increased titers with 
mannose supplementation but 
not glucose (open square) or 
fructose (open diamond). 
